de State Street Vanda Pharmaceuticals VNDA Historial de posiciones en acciones
Compró
Mantenido
Vendió
| Trimestre | Valor de mercado | Estado | Núm. de acciones |
Cambio en la participación | Valor operado | Peso en el portafolio | Posición de la cartera | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | USD 21.5 M | Comprar |
3,516,405
+500,843
| +17% | +USD 3.27 M | ﹤0.01% | 2338 |
|
|
2026
Q1 | USD 20.8 M | Comprar |
3,015,562
+1,752,023
| +139% | +USD 13.5 M | ﹤0.01% | 2221 |
|
|
2025
Q4 | USD 11.1 M | Vender |
1,263,539
-7,540
| -0.6% | -USD 41.5 k | ﹤0.01% | 2595 |
|
|
2025
Q3 | USD 6.34 M | Comprar |
1,271,079
+5,232
| +0.4% | +USD 24.2 k | ﹤0.01% | 2889 |
|
|
2025
Q2 | USD 5.97 M | Comprar |
1,265,847
+13,288
| +1% | +USD 58.1 k | ﹤0.01% | 2855 |
|
|
2025
Q1 | USD 5.75 M | Comprar |
1,252,559
+68,696
| +6% | +USD 320 k | ﹤0.01% | 2819 |
|
|
2024
Q4 | USD 5.67 M | Comprar |
1,183,863
+18,681
| +2% | +USD 89.7 k | ﹤0.01% | 2911 |
|
|
2024
Q3 | USD 5.46 M | Vender |
1,165,182
-46,127
| -4% | -USD 247 k | ﹤0.01% | 2923 |
|
|
2024
Q2 | USD 6.84 M | Comprar |
1,211,309
+8,014
| +0.7% | +USD 41.4 k | ﹤0.01% | 2773 |
|
|
2024
Q1 | USD 4.95 M | Vender |
1,203,295
-24,801
| -2% | -USD 99.3 k | ﹤0.01% | 2930 |
|
|
2023
Q4 | USD 5.18 M | Vender |
1,228,096
-75,685
| -6% | -USD 305 k | ﹤0.01% | 2930 |
|
|
2023
Q3 | USD 5.63 M | Vender |
1,303,781
-2,776,855
| -68% | -USD 15.4 M | ﹤0.01% | 2866 |
|
|
2023
Q2 | USD 26.9 M | Vender |
4,080,636
-471,276
| -10% | -USD 3.02 M | ﹤0.01% | 2057 |
|
|
2023
Q1 | USD 30.9 M | Comprar |
4,551,912
+824,114
| +22% | +USD 5.79 M | ﹤0.01% | 1952 |
|
|
2022
Q4 | USD 27.5 M | Comprar |
3,727,798
+42,447
| +1% | +USD 413 k | ﹤0.01% | 2015 |
|
|
2022
Q3 | USD 36.4 M | Vender |
3,685,351
-30,574
| -0.8% | -USD 323 k | ﹤0.01% | 1820 |
|
|
2022
Q2 | USD 40.5 M | Vender |
3,715,925
-347,373
| -9% | -USD 3.6 M | ﹤0.01% | 1790 |
|
|
2022
Q1 | USD 46 M | Comprar |
4,063,298
+735,865
| +22% | +USD 9.7 M | ﹤0.01% | 1819 |
|
|
2021
Q4 | USD 52.2 M | Vender |
3,327,433
-70,609
| -2% | -USD 1.23 M | ﹤0.01% | 1776 |
|
|
2021
Q3 | USD 58.2 M | Comprar |
3,398,042
+236,533
| +7% | +USD 4.14 M | ﹤0.01% | 1702 |
|
|
2021
Q2 | USD 68 M | Vender |
3,161,509
-150,830
| -5% | -USD 2.7 M | ﹤0.01% | 1614 |
|
|
2021
Q1 | USD 49.8 M | Comprar |
3,312,339
+108,435
| +3% | +USD 1.76 M | ﹤0.01% | 1752 |
|
|
2020
Q4 | USD 42.1 M | Vender |
3,203,904
-181,430
| -5% | -USD 2.18 M | ﹤0.01% | 1745 |
|
|
2020
Q3 | USD 32.7 M | Vender |
3,385,334
-293,278
| -8% | -USD 3.13 M | ﹤0.01% | 1742 |
|
|
2020
Q2 | USD 42.1 M | Comprar |
3,678,612
+842,696
| +30% | +USD 9.5 M | ﹤0.01% | 1561 |
|
|
2020
Q1 | USD 29.4 M | Comprar |
2,835,916
+301,896
| +12% | +USD 3.74 M | ﹤0.01% | 1587 |
|
|
2019
Q4 | USD 41.6 M | Vender |
2,534,020
-331,817
| -12% | -USD 5.02 M | ﹤0.01% | 1638 |
|
|
2019
Q3 | USD 38.1 M | Vender |
2,865,837
-134,979
| -4% | -USD 1.88 M | ﹤0.01% | 1634 |
|
|
2019
Q2 | USD 42.3 M | Vender |
3,000,816
-671,993
| -18% | -USD 10.7 M | ﹤0.01% | 1590 |
|
|
2019
Q1 | USD 67.6 M | Comprar |
3,672,809
+1,200,854
| +49% | +USD 27.4 M | 0.01% | 1267 |
|
|
2018
Q4 | USD 64.6 M | Vender |
2,471,955
-59,786
| -2% | -USD 1.41 M | 0.01% | 1195 |
|
|
2018
Q3 | USD 58.1 M | Comprar |
2,531,741
+358,730
| +17% | +USD 7.32 M | ﹤0.01% | 1431 |
|
|
2018
Q2 | USD 41.4 M | Comprar |
2,173,011
+288,921
| +15% | +USD 4.83 M | ﹤0.01% | 1601 |
|
|
2018
Q1 | USD 31.7 M | Vender |
1,884,090
-251,137
| -12% | -USD 4.2 M | ﹤0.01% | 1735 |
|
|
2017
Q4 | USD 32.5 M | Comprar |
2,135,227
+486,595
| +30% | +USD 7.22 M | ﹤0.01% | 1734 |
|
|
2017
Q3 | USD 29.5 M | Comprar |
1,648,632
+30,147
| +2% | +USD 504 k | ﹤0.01% | 1737 |
|
|
2017
Q2 | USD 26.4 M | Comprar |
1,618,485
+46,299
| +3% | +USD 667 k | ﹤0.01% | 1803 |
|
|
2017
Q1 | USD 22 M | Vender |
1,572,186
-179,419
| -10% | -USD 2.56 M | ﹤0.01% | 1874 |
|
|
2016
Q4 | USD 27.9 M | Comprar |
1,751,605
+374,095
| +27% | +USD 6.01 M | ﹤0.01% | 1655 |
|
|
2016
Q3 | USD 22.9 M | Comprar |
1,377,510
+92,456
| +7% | +USD 1.24 M | ﹤0.01% | 1692 |
|
|
2016
Q2 | USD 14.4 M | Vender |
1,285,054
-203,313
| -14% | -USD 1.97 M | ﹤0.01% | 1984 |
|
|
2016
Q1 | USD 12.4 M | Vender |
1,488,367
-200,399
| -12% | -USD 1.64 M | ﹤0.01% | 2043 |
|
|
2015
Q4 | USD 15.7 M | Vender |
1,688,766
-799,413
| -32% | -USD 7.98 M | ﹤0.01% | 1890 |
|
|
2015
Q3 | USD 28.1 M | Vender |
2,488,179
-81,438
| -3% | -USD 996 k | ﹤0.01% | 1516 |
|
|
2015
Q2 | USD 32.6 M | Vender |
2,569,617
-115,978
| -4% | -USD 1.25 M | ﹤0.01% | 1531 |
|
|
2015
Q1 | USD 25 M | Comprar |
2,685,595
+808,011
| +43% | +USD 9.13 M | ﹤0.01% | 1696 |
|
|
2014
Q4 | USD 26.9 M | Comprar |
1,877,584
+65,250
| +4% | +USD 772 k | ﹤0.01% | 1582 |
|
|
2014
Q3 | USD 18.8 M | Comprar |
1,812,334
+260,416
| +17% | +USD 3.41 M | ﹤0.01% | 1789 |
|
|
2014
Q2 | USD 25.1 M | Vender |
1,551,918
-2,512
| -0.2% | -USD 33.5 k | ﹤0.01% | 1656 |
|
|
2014
Q1 | USD 25.3 M | Comprar |
1,554,430
+988,158
| +175% | +USD 14 M | ﹤0.01% | 1599 |
|
|
2013
Q4 | USD 7.02 M | Comprar |
566,272
+41,440
| +8% | +USD 416 k | ﹤0.01% | 2376 |
|
|
2013
Q3 | USD 5.76 M | Comprar |
524,832
+14,314
| +3% | +USD 153 k | ﹤0.01% | 2454 |
|
|
2013
Q2 | USD 4.12 M | Comprar |
+510,518
| Nuevas | +USD 3.44 M | ﹤0.01% | 2576 |
|
Otros fondos que tienen VNDA en su cartera
ACM
Posición de State Street en VNDA: resumen de T2 2026
State Street aumentó su participación en Vanda Pharmaceuticals (VNDA) en 17% durante T2 2026, al comprar aproximadamente USD 3.27 M y elevar la posición a 3,516,405 acciones con un valor de USD 21.5 M. La posición representa ﹤0.01% de la cartera y ocupa el puesto #2338.
State Street reportó por primera vez una posición en VNDA en T2 2013 y la ha mantenido durante 53 trimestres desde entonces. La posición alcanzó su máximo de USD 68 M en T2 2021. Al cierre de T2 2026, 172 fondos que sigue Wall St. Rank mantienen una posición en VNDA.
- Al cierre de T2 2026, State Street tenía 3,516,405 acciones de Vanda Pharmaceuticals con un valor de USD 21.5 M.
- State Street compró 500,843 acciones de Vanda Pharmaceuticals en T2 2026, por un monto estimado de USD 3.27 M.
- Vanda Pharmaceuticals representó ﹤0.01% de la cartera de State Street en T2 2026 y fue su posición número 2338.
- State Street reportó por primera vez una posición en Vanda Pharmaceuticals en T2 2013 y la ha mantenido durante 53 trimestres desde entonces.
- La posición de State Street en Vanda Pharmaceuticals alcanzó su máximo de USD 68 M en T2 2021.
- Al cierre de T2 2026, 172 fondos que sigue Wall St. Rank tenían Vanda Pharmaceuticals en cartera.
Según el Informe 13F de State Street correspondiente a T2 2026, presentado el 7 ago 2026.